---
title: "Ernexa Therapeutics holds annual shareholder meeting"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/291586277.md"
description: "Ernexa Therapeutics held its annual shareholder meeting on July 1, 2027. Key outcomes included the election of five directors for terms until the next annual meeting, the ratification of Haskell & White LLP as the independent registered public accounting firm for fiscal 2026, and the approval of the 2026 Omnibus Equity Incentive Plan."
datetime: "2026-07-02T20:32:45.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/291586277.md)
  - [en](https://longbridge.com/en/news/291586277.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/291586277.md)
generator: "portal-rs"
---

# Ernexa Therapeutics holds annual shareholder meeting

-   Ernexa Therapeutics held its annual stockholder meeting on July 1, 2027. \* Stockholders elected five directors to serve until the 2027 annual meeting. \* Appointment of Haskell & White LLP as independent registered public accounting firm for fiscal 2026 was ratified. \* Adoption of the 2026 Ernexa Therapeutics Omnibus Equity Incentive Plan was approved. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Ernexa Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001493152-26-031920), on July 02, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT) Original Document: here

### Related Stocks

- [ERNA.US](https://longbridge.com/en/quote/ERNA.US.md)

## Related News & Research

- [Rapport Therapeutics Chief Development Officer Krishnaswamy Yeleswaram disposes of 404 common shares worth $20,159.6](https://longbridge.com/en/news/296531261.md)
- [Nykode Therapeutics to release Q2 financial results, host webcast presentation](https://longbridge.com/en/news/296641436.md)
- [Palvella Therapeutics COO Kathleen Goin reports sale of 4,302 common shares worth $654,184.41](https://longbridge.com/en/news/296530942.md)
- [Pelthos Therapeutics announces annual shareholder meeting](https://longbridge.com/en/news/296270309.md)
- [Maze Therapeutics director Paula A. Johnson files initial beneficial ownership statement](https://longbridge.com/en/news/296144789.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**